Peter Sandner
11Patents
1h-index
33Co-inventors
50Inventor score
Filing activity: Apr 3, 2007 → Apr 13, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10189856B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | Chemistry; Metallurgy | 3 | Active |
| US8304406B2 | Compounds for treating pulmonary hypertension | Emerging Cross-Sectional Technologies | 1 | Active |
| US10918639B2 | Combination containing SGC stimulators and mineralocorticoid receptor antagonists | Human Necessities | 1 | Active |
| US11331308B2 | Combination containing sGC activators and mineralocorticoid receptor antagonists | Human Necessities | 0 | Active |
| US11508483B2 | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group | Physics | 0 | Active |
| US9040566B2 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | Chemistry; Metallurgy | 0 | Active |
| US10265314B2 | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | Human Necessities | 0 | Active |
| US12195448B2 | Substituted pyrazolo piperidine carboxylic acids | Chemistry; Metallurgy | 0 | Active |
| US12098140B2 | Substituted pyrazolo piperidine carboxylic acids | General | 0 | Revoked |
| US11684621B2 | Combination containing sGC stimulators and mineralocorticoid receptor antagonists | Human Necessities | 0 | Active |
| US11439628B2 | Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.